This Bull Market Indicator called NVDA at $116

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

Nathalie Adda Biography and Net Worth

VP of Enanta Pharmaceuticals

Dr. Adda joined Enanta in June 2015. Dr. Adda is a specialist in infectious disease and has more than 20 years of experience in the pharmaceutical industry in all phases of global clinical research and development and commercialization. Most recently, Dr. Adda was Chief Medical Officer, VP Clinical Development, Medical and Regulatory Affairs at Transgene SA, where she led the Oncology and Infectious Disease programs since 2012. From 2006 to 2012, she was Senior Medical Director and the medical lead for the Incivek® (telaprevir) Clinical Program at Vertex Pharmaceuticals Inc., where she designed the phase 2 and Phase 3 programs, and led the medical team in its successful marketing applications and registration in the USA, Canada, and, Asia. Earlier in her career, she held medical and research positions at Gilead, Triangle Pharmaceuticals and Boehringer Ingelheim, where she worked on programs for infectious diseases such as human immunodeficiency virus, hepatitis B virus and hepatitis C virus.

Dr. Adda is a graduate of the University of Paris, where she received a Doctorate in Medicine, as well as a Master’s Degree in Biostatistics, and where she did post-graduate work in infectious diseases.

What is Nathalie Adda's net worth?: The estimated net worth of Nathalie Adda is at least $313,088.90 as of April 1st, 2022. Dr. Adda owns 34,982 shares of Enanta Pharmaceuticals stock worth more than $313,089 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Adda may own. Learn More about Nathalie Adda's net worth.
How do I contact Nathalie Adda?: The corporate mailing address for Dr. Adda and other Enanta Pharmaceuticals executives is 500 ARSENAL STREET, WATERTOWN MA, 02472. Enanta Pharmaceuticals can also be reached via phone at (617) 607-0800 and via email at [email protected]. Learn More on Nathalie Adda's contact information.
Has Nathalie Adda been buying or selling shares of Enanta Pharmaceuticals?: Nathalie Adda has not been actively trading shares of Enanta Pharmaceuticals during the last quarter. Most recently, Nathalie Adda sold 32,785 shares of the business's stock in a transaction on Monday, April 4th. The shares were sold at an average price of $72.18, for a transaction totalling $2,366,421.30. Following the completion of the sale, the vice president now directly owns 34,982 shares of the company's stock, valued at $2,525,000.76. Learn More on Nathalie Adda's trading history.
Who are Enanta Pharmaceuticals' active insiders?: Enanta Pharmaceuticals' insider roster includes Nathalie Adda (VP), Jay Luly (CEO), and Paul Mellett, Jr. (Sr. VP of Fin. & Admin. and CFO ). Learn More on Enanta Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Enanta Pharmaceuticals?: During the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 44,536 shares worth more than $504,129.74. The most recent insider tranaction occured on July, 15th when insider Scott T Rottinghaus sold 5,375 shares worth more than $91,805.00. Insiders at Enanta Pharmaceuticals own 13.6% of the company. Learn More about insider trades at Enanta Pharmaceuticals.
Information on this page was last updated on 7/15/2024.

Nathalie Adda Insider Trading History at Enanta Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/4/2022	Sell	32,785	$72.18	$2,366,421.30	34,982
4/1/2022	Sell	50,559	$71.23	$3,601,317.57	34,982
3/1/2022	Sell	24,339	$70.26	$1,710,058.14
1/11/2022	Sell	12,536	$70.13	$879,149.68
12/1/2021	Sell	13,523	$86.35	$1,167,711.05
11/1/2021	Sell	9,547	$84.89	$810,444.83
10/11/2021	Sell	4,047	$70.34	$284,665.98
10/8/2021	Sell	13,453	$70.09	$942,920.77
9/20/2018	Sell	4,155	$95.32	$396,054.60	4,155
8/20/2018	Sell	4,155	$92.32	$383,589.60	4,465
7/18/2018	Sell	5,045	$124.84	$629,817.80	6,555
6/18/2018	Sell	4,155	$114.85	$477,201.75	7,755
5/16/2018	Sell	4,155	$105.25	$437,313.75	8,955
4/16/2018	Sell	4,225	$85.58	$361,575.50	10,225

Nathalie Adda Buying and Selling Activity at Enanta Pharmaceuticals

Enanta Pharmaceuticals Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $8.95

$8.95

$9.16

50 Day Range

MA: $11.20

$9.08

$13.00

2 Week Range

Now: $8.95

$8.51

$17.80

Volume

32,355 shs

Average Volume

195,799 shs

Market Capitalization

$189.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

My #1 Pre IPO Trade for 2025 – NAME and TICKER

From Wyatt Investment Research | Ad

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

The Next SpaceX Pre-IPO